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ABSTRACT 
Objective: The risk of gastrointestinal bleeding (GIB) in aspirin users after H. pylori 
(HP) eradication remains poorly defined. We characterized the incidences and temporal 
trends of hospitalizations for all GIB in aspirin users after HP eradication therapy. 
Design: Based on a territory-wide health database, we identified all patients who had 
received the first course of clarithromycin-based triple therapy between 2003 and 2012. 
Patients were divided into three cohorts according to aspirin use: new users 
(commenced after HP eradication), chronic users (commenced before and resumed after 
HP eradication) and non-users. The primary outcome was to determine the risk of 
hospitalization for GIB. 
Results: We included 6,985 new aspirin users, 5,545 chronic users, and 48,908 non-
users. The age- and sex-adjusted incidence of hospitalization for all GIB in new, chronic 
and non-users was 10.4, 7.2 and 4.6 per 1000 person-years, respectively. Upper and 
lower GIB accounted for 34.7% and 45.3% of all bleeding, respectively. Compared to 
chronic users, new users had a higher risk of GIB (hazards ratio [HR] with propensity 
score matching: 1.89; 95% CI 1.29-2.70). Landmark analysis showed that the increased 
risk in new aspirin users was only observed in the first 6-month for all GIB (HR 2.10, 
95% CI 1.41-3.13) and upper GIB (HR 2.52, 95% CI 1.38-4.60), but not for lower GIB. 
Conclusion: New aspirin users had a higher risk of GIB than chronic aspirin users, 
particularly during the initial 6-month. Lower GIB is more frequent than UGIB in 
aspirin users who had HP eradicated.   
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SIGNIFICANCE OF THE STUDY 
What is already known about this subject? 
 H. pylori eradication has been shown to reduce the risk of upper gastrointestinal 
bleeding (GIB) in patients newly started on aspirin. 
 Aspirin is also increasingly recognized to be an important cause of lower GIB. 
 However, the long term risks and temporal patterns of GIB, including upper and 
lower, among new or chronic aspirin users who had H. pylori eradicated remain 
uncertain. 
What are the new findings? 
 We found that the risk of GIB, both upper and lower, were significantly higher 
among new or chronic aspirin users when compared to non-users in a territory-wide 
cohort of H. pylori infected patients who had received eradication therapy. 
 New aspirin users had a significantly higher risk of GIB, especially upper GIB, than 
chronic aspirin users, particularly during the initial 6-month of aspirin therapy. 
 Although the incidence of LGIB was even more frequent than upper GIB after 
treatment for H. pylori, similar decline in the risk of lower GIB between new and 
chronic aspirin users was not observed. 
How might it impact on clinical practice in the foreseeable future? 
 New aspirin users still have an increase in risk of GIB even after eradication of H. 
pylori, particularly during the initial 6-month of aspirin therapy.  
 Lower GI tract appears to be an important source of bleeding among aspirin users 
who had H. pylori eradicated. 
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INTRODUCTION 
Acute gastrointestinal bleeding (GIB) is one of the most common causes of 
hospitalization and emergency visit, resulting in a substantial economic burden on the 
health care system. In the United States, GIB accounted for more than 500,000 
hospitalizations and consumed $4.85 billion in 2012.1 Helicobacter pylori (H. pylori) 
infection, non-steroidal anti-inflammatory drugs (NSAIDs) and low-dose aspirin uses 
are generally considered to be the most important risk factors in the pathogenesis of 
peptic ulcers as well as the causes of non-variceal upper gastrointestinal bleeding 
(UGIB).2, 3 With the widespread use of H. pylori eradication therapy, the prevalence of 
H. pylori infection had been declining globally.4 However, with the aging population, 
aspirin is increasingly used in the prevention of cardiovascular or cerebrovascular 
events5, giving rise to the increasing proportion of patients with UGIB due to aspirin. 
While both H. pylori infection and aspirin are risk factors for peptic ulcer and its 
complications, H. pylori eradication has been shown to reduce the risk of GIB in low-
dose aspirin users.6-8 H. pylori eradication is therefore recommended in long-term 
aspirin users, especially high-risk patients.8-10  
Apart from UGIB, aspirin is increasingly recognized to be associated with lower 
gastrointestinal bleeding (LGIB).11, 12 Although H. pylori eradication and the use of 
gastroprotective agents, including proton pump inhibitors (PPI) and histamine type-2 
receptor antagonists (H2RA), could reduce the risk of UGIB, the risk of LGIB remains. 
There is a significant knowledge gap about the natural history of all-cause GIB, 
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including upper and lower GIB, among aspirin users who had H. pylori eradicated. The 
issue is further complicated by the potential adaptive effects of the gastric mucosa to 
aspirin, in which aspirin associated UGIB tend to occur at the early course of treatment 
13,14. As yet, whether there is similar adaptive effect to aspirin in the lower 
gastrointestinal tract remains unknown. 
Based on a large cohort of H. pylori-eradicated patients from Hong Kong, we 
characterized the incidences, temporal trends and risks of hospitalizations for all-cause 
GIB, including UGIB and LGIB, in new aspirin users as compared to chronic users and 
non-users. 
 
METHODS 
Data source 
All data were retrieved from the Clinical Data Analysis and Reporting System (CDARS) 
of the Hong Kong Hospital Authority. The Hospital Authority is the only public 
healthcare provider of Hong Kong with more than 7 million residents. The CDARS is 
a centralized electronic system which records all patients’ clinical information 
including demographics, diagnoses, prescriptions, treatment, hospitalization and 
death.15-17 All records were anonymized to protect patients’ confidentiality, and a 
unique numeric identifier was assigned to each patient. The International Classification 
of Diseases, Ninth Revision (ICD-9) was used for disease coding and the accuracy of 
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coding for GIB had been previously verified.16 This study was approved by the 
Institutional Review Board of the University of Hong Kong and the Hospital Authority 
Hong Kong West Cluster (Reference number: UW 16-545). 
 
Study subjects and study design 
We have previously identified a large cohort of H. pylori-infected patients who had 
received clarithromycin-based triple eradication therapy in Hong Kong between 1 
January 2003 and 31 December 2012.17, 18 In this study, we analyzed the risk of 
hospitalization for GIB in this cohort who used aspirin after H. pylori eradication. 
Patients who were newly started on aspirin after H. pylori eradication, but who had not 
used any aspirin within two years before the eradication, were classified as new users. 
Patients who used aspirin both before and after H. pylori eradication therapy were 
classified as chronic users, whereas those who had never used aspirin both before and 
after H. pylori eradication were labelled as non-users (Supplementary Figure 1). 
Patients who used aspirin before H. pylori eradication but did not resume on aspirin 
after the eradication therapy were excluded. 
Since post-eradication H. pylori statuses were not available in the electronic database, 
we excluded patients who required re-treatment for H. pylori as described previously.17 
Other exclusion criteria included patients with follow up less than 7 days, patients who 
had gastrointestinal cancer, inflammatory bowel disease, coagulant deficiency, 
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gastroenteritis or colitis due to radiation, and excision of gastrointestinal tract segment. 
In addition,  
 
Outcome and covariates 
The primary outcome was to determine the incidences of hospitalization for GIB in new 
aspirin users, chronic users and non-users after H. pylori eradication therapy, and to 
compare the risk of GIB in new users with chronic users. The risk factors of GIB among 
all aspirin users were also evaluated. The start point of the follow-up period for all 
aspirin users was the date of starting or resuming aspirin after H. pylori eradication 
therapy. The end-point was the occurrence of GIB, 30 days after aspirin discontinuation, 
death, or the end of the study at 30 June 2016. The maximum observation period was 
set as 10 years. Discontinuation of aspirin was defined as an interruption for more than 
30 days between two aspirin prescriptions. Since there was no definite start date for 
non-users, the start date was arbitrarily set as 60 days after H. pylori eradication. The 
60 days was chosen to allow for the healing of possible peptic ulcer, which may falsely 
increase the bleeding rate.19 A sensitivity analysis was also performed to use 7 days 
after eradication as start date for non-users. 
The primary end point was hospitalization for non-variceal GIB, which was retrieved 
using the ICD-9 codes of UGIB, LGIB and unspecified GIB (578.xx, Supplementary 
Table 1). Hematemesis (578.0) and melena or black tarry stool (578.1) were regarded 
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as UGIB, whereas hematochezia from 578.1 was taken as LGIB in this study. For other 
diagnoses with the code of 578.xx, the specific bleeding site would be used if the 
description of the diagnosis had mentioned the bleeding location. Moreover, if there 
were new specific diagnoses within 30 days, the diagnosis of unspecified GIB would 
be renewed with the original index date unchanged. As a secondary outcome, the risk 
of in-hospital mortality was also evaluated, which was defined as death during the 
hospitalization for GIB. 
Baseline characteristics of the patients, their comorbid medical conditions and 
concurrent medications were included as covariates in binary variables. Pre-existing 
medical conditions before enrollment were extracted using ICD-9 codes including 
history of GIB or peptic ulcer, hypertension, ischemic heart disease, stroke (ischemic 
stroke, transient ischemic attack or systemic embolism), diabetes, renal disease, 
intracranial hemorrhage, and liver cirrhosis. Concurrent medications (Supplementary 
Table 2) used during the follow-up period which could potentially alter the bleeding 
risk were also included: gastroprotective agents including PPI and H2RA, other 
antiplatelet drugs, NSAIDs, anticoagulants, corticosteroids, selective serotonin 
reuptake inhibitors (SSRI) and bisphosphonate. Drug usage was defined as more than 
7 days use during the follow-up period. To reduce potential indication bias for 
gastroprotective agents, PPI and H2RA prescription records within the last 4 weeks of 
the event date or censor date were excluded. 
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Statistical analysis 
Continuous variables were expressed as median and interquartile range (IQR), while 
categorical variables were presented as frequencies and percentages. Mann-Whitney U 
test was used for continuous variables and Chi-square test or Fisher’s exact test was 
used for categorical variables. Incidence rates and relative risks (RR) among new, 
chronic aspirin users and non-users were calculated. The in-hospital mortality rate of 
GIB was also determined. 
The risks of hospitalization for GIB among new, chronic users and non-users were 
illustrated by fitting Kaplan-Meier curves and the differences were tested using the log-
rank test. Cox proportional hazards regression model was used and the bleeding risk 
was expressed in hazards ratios (HR) with 95% confidence intervals (CI). When fitting 
a Cox regression model, the proportional hazards assumption was checked using 
Schoenfeld test and graphical diagnostics by plotting the scaled Schoenfeld residuals 
against the survival times.20, 21 Once violation of this assumption was observed, 
interactions of time-dependent covariates with time would be introduced into the 
regression model.21 In multivariable Cox regression model, concurrent medications 
were included as time-varying covariates, of which the follow-up period was split into 
3-monthly intervals and drug usage was defined in each interval as more than 7 days 
use. In all regression models, aspirin use was included as a time-varying variable. 
To balance the potential differences in the baseline characteristics between new and 
chronic users, the propensity score (PS) matching method was performed using the 
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nearest-neighbor algorithm with a ratio of 1:1 and calipers of width equaling to 0.2. In 
addition, matching weighting (MW), inverse probability of treatment weighting (IPTW) 
method were also performed.22, 23 Absolute standardized differences (ASD) were used 
to compare the mean or prevalence of covariates between groups to identify for 
imbalance.24 An ASD ≥0.1 denotes imbalance of baseline characteristics. Therefore, 
Cox regression models were also fitted with the PS matched, and weighted (MW and 
IPTW) samples. A competing risk analysis was also performed with PS matched 
samples, in which death was considered to be a competing event for GIB. To better 
interpret the temporal trend of bleeding risk in new versus chronic users, landmark 
analyses were performed.25, 26 The HRs were calculated separately in each 
observational interval, adjusting for all other covariates. A two-sided P value less than 
0.05 were regarded as statistically significant. The R version 3.4.2 (R Foundation for 
Statistical Computing, Vienna, Austria, 2017) was used in all statistical analyses. 
 
RESULTS 
Patient characteristics 
Of the 74,612 subjects who had received clarithromycin-based triple therapy for H. 
pylori during the study period, we identified 6,985 new and 5,545 chronic aspirin users, 
as well as 48,908 non-users (Supplementary Figure 2). The characteristics of all 
eligible patients are shown in Table 1. The median follow-up duration of new, chronic 
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and non-users was 1.48 (IQR 0.42, 3.74), 4.09 (IQR 1.27-6.99) and 7.68 (IQR 5.29-10) 
years, respectively (P < 0.001). The daily dosage of aspirin, expressed in person-days, 
was <100 mg in 84.1%. 
 
Incidences of hospitalization for GIB 
During the follow-up period, 261 (3.74%) new aspirin users, 303 (5.46%) chronic users 
and 1,295 (2.65%) non-users had hospitalizations for GIB. The corresponding age- and 
sex-adjusted incidence rate of GIB was 10.4 (95% CI 7.9-66.4), 7.2 (95% CI 6.3-157.7) 
and 4.6 (95% CI 4.4-4.9) per 1,000 person-years, respectively. After stratified by 
bleeding sites, UGIB and LGIB accounted for 34.7% and 45.3% of all GIB, respectively. 
For all aspirin users, the proportion of UGIB was 37.2% and LGIB was 40.8%. The 
adjusted incidence rate of UGIB for new, chronic and non-users were 3.0 (95% CI 2.4-
61.2), 2.6 (95% CI 2.1-155.1), 1.7 (95% CI 1.5-1.9) per 1,000 person-years, 
respectively. The corresponding figures of LGIB for the three groups was 5.7 (95% CI 
3.5-63.1), 3.0 (95% CI 2.4-155.3) and 1.9 (95% CI 1.7-2.1) per 1,000 person-years. The 
detailed sources of GIB in all patients are shown in the Supplementary Table 3. 
Both new and chronic aspirin users had higher crude incidence rates of hospitalization 
for all GIB, UGIB and LGIB as compared with non-users, and the difference was 
significant in each time intervals during follow-up (Figure 1). This was consistent in 
Kaplan-Meier curves for all GIB (log-rank test P < 0.001; Figure 2A). In the 
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multivariable Cox model, increased risk of GIB was observed in both new (HR 1.92, 
95% CI 1.62-2.27) and chronic users (HR 1.44, 95% CI 1.19-1.74), when compared to 
non-users. Similar results were obtained when the start date of follow up of non-users 
was changed to 7 days after H. pylori eradication (new users vs. non-users: HR 1.95, 
95% CI 1.65-2.31; chronic users vs. non-users: HR 1.44, 95% CI 1.20-1.74). 
When compared to chronic users, new users had a higher incidence rate of 
hospitalization for all GIB (RR 1.25, 95% CI 1.06-1.47). Due to the difference in 
baseline characteristics between the new and chronic users, we have used various 
models, including PS matching, MW, IPTW and multivariable model to adjust for these 
differences (Supplementary Figure 3), to show that new users still had a higher risk 
of GIB when compared to chronic users (Figure 2B, HR with PS matching: 1.89; 95% 
CI 1.29-2.70 and Table 2). The result was also consistent in the competing risk 
regression (HR 1.79, 95% CI 1.09-2.97). 
 
Data Validation 
To validate the final H. pylori statuses of patients who had UGIB after H. pylori 
eradication, we retrieved the final H. pylori statuses of 51 patients from our center. 
Among them, only two (3.9%) were found to be positive including one patient who was 
negative by urea breath test post-treatment but became positive upon re-examination 
during GIB. 
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In-hospital mortality of GIB 
The in-hospital mortality rate of GIB for new, chronic and non-users was 9.6% (25/261), 
9.6% (29/303) and 5.3% (69/1,295), respectively. In multivariable model, new users 
(HR 2.23, 95% CI 1.18-4.22) were associated with a higher risk of in-hospital mortality 
than non-users. There was no significant difference between chronic users and non-
users (HR 1.87, 95% CI 0.97-3.60), as well as between new and chronic users (HR 1.47, 
95% CI 0.72-3.01). 
 
Time trend of hospitalization for GIB in aspirin users 
The crude incidence rates of hospitalization for GIB in both new and chronic users 
showed a declining trend with time (Figure 1). When comparing new with chronic 
users, the elevated risk of all GIB decreased over time in all models except for PS 
matching, where a borderline CI was noted (HR 0.89, 95% CI 0.80-1.01; Table 2 and 
Supplementary Figure 4). Specifically, the difference in the incidences of GIB 
between new and chronic users was only significant in the first two years for all GIB 
(RR 1.35, 95% CI 1.07−1.7) and UGIB (RR 1.49, 95% CI 1.02−2.17; Figure 1). In the 
landmark analysis of all GIB, the risk of GIB associated with new aspirin use was 
significantly higher in the first 6 months (HR 2.10, 95% CI 1.41-3.13; Figure 3A), but 
not in the following period (HR 1.18, 95% CI 0.93-1.50). The result was consistent with 
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the landmark analysis of UGIB (0-6 months: HR 2.52, 95% CI 1.38-4.60; >6 months: 
HR 0.96, 95% CI 0.64-1.45; Figure 3B). Similar decline in LGIB risk between new 
and chronic aspirin users was not detected (Schoenfeld test in multivariable Cox model, 
P = 0.934). 
 
Factors associated with hospitalization for GIB among aspirin users 
In multivariable model with all aspirin users, we confirmed that new aspirin users had 
higher risk of GIB than chronic users (HR 1.74, 95% CI 1.32-2.29, Figure 4). Other 
risk factors of GIB included past history of GIB or ulcer (HR 2.78, 95% CI 2.15-3.60), 
renal disease (HR 2.25, 95% CI 1.65-3.08), stroke (HR 1.50, 95% CI 1.07-2.12), use of 
other antiplatelet drugs (HR 1.49, 95% CI 1.11-2.00), NSAIDs (HR 1.64, 95% CI 1.14-
2.35), corticosteroids (HR 1.91, 95% CI 1.29-2.35) and older age (HR 1.05, 95% CI 
1.03-1.06). Subgroup analysis further showed that new aspirin users had higher risk of 
GIB both in patients with (HR 1.93, 95% CI 1.27-2.94) or without history of GIB or 
ulcer (HR 1.58, 95% CI 1.09-2.28). 
On the other hand, the use of gastroprotective agents was associated with a lower risk 
of GIB (HR 0.34, 95% CI 0.25-0.46) in aspirin users, including the use of PPI (HR 0.46, 
95% CI 0.36-0.58) and H2RA (HR 0.43, 95% CI 0.32-0.56). Benefits of 
gastroprotective agents on lowering risk of GIB were also found in other subgroups 
including elderly ( 60 years), those who had concurrent use of aspirin with NSAIDs 
or other antiplatelet therapies (Supplementary Table 4). 
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DISCUSSION 
While H. pylori infection and aspirin are both important risk factors for UGIB,27 
elimination of H. pylori infection would leave aspirin and/or NSAIDs to be the major 
risk factor(s) for UGIB.4, 12 Hence, study on H. pylori eradicated subjects could possibly 
delineate the natural history of aspirin related GIB. This is the first study to characterize 
the incidences, temporal trends and risk factors of hospitalization for all GIB, including 
both upper and lower GIB, in a large cohort of H. pylori-infected patients who had 
received eradication therapy and were then newly started on aspirin or continued to use 
aspirin. We found that the incidences of GIB, including upper and lower GIB, in both 
new and chronic aspirin users were significantly higher than non-users. More 
importantly, we showed that new aspirin users had a 1.9-fold (PS matched analysis) 
higher risk of GIB when compared to chronic users. The risk of GIB, particularly UGIB, 
was significantly increased in new aspirin users during the initial 6-month of aspirin 
therapy in landmark analyses. 
The risk of GIB and UGIB in new aspirin users, when compared to chronic users, 
decreased with time in most models, suggesting that the bleeding risk in aspirin users 
is time-dependent. Slattery et al showed that UGIB were three times more likely to 
occur in the initial 152 days of aspirin treatment.14 Apart from aspirin, current literature 
also suggests that GIB are more likely to occur in the early course of treatment with 
NSAIDs, antiplatelet drugs, or dual antiplatelet therapy.14, 28-30 Although previous 
studies have demonstrated the potential gastric adaptation to aspirin6 31, 32, these studies 
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failed to address the issue of concurrent H. pylori infection, which is an important 
confounding factor for UGIB. Our findings further showed that the gastric adaptive 
effects may not be related to H. pylori and remain even after eradication therapy. 
Arguably, the observed difference between new and chronic users could be accounted 
by the depletion of susceptible patients in chronic users who would have developed 
bleeding and then stopped aspirin treatment. In addition, the increase in early bleeding 
risk of new users could be explained by the effect of aspirin upon pre-existing gastric 
pathology, which may lead to early bleeding. 
In this study, we showed that new users had a higher in-hospital mortality of GIB than 
non-users, but there was no difference in mortality between chronic and new users or 
between chronic users and non-users. Thus far, data on aspirin and GIB mortality 
remains conflicting. Studies have shown that aspirin use was associated with a 
reduction in the risk of adverse outcomes in patients with UGIB.33, 34 On the other hand, 
there was reports of no increase in mortality of aspirin-related GIB.35, 36 These 
discrepancies may be related to the difference in patient characteristics including H. 
pylori infection, timings of aspirin use (before or after GIB) and comorbidities 
(particularly underlying ischemic diseases). 
It is important to note that after treatment for H. pylori, LGIB accounted for about 45.3% 
of all GIB, which was even higher than UGIB. This may be a consequence of both H. 
pylori eradication and use of gastroprotective agents. In this study, more than 74% of 
patients were taking gastroprotective agents. LGIB was also significantly more frequent 
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in both new and chronic aspirin users when compared to non-users. However, similar 
decline in the risk of LGIB with time between new and chronic aspirin users was not 
observed. Hence, similar adaptation of the small or large intestinal mucosa to aspirin 
may not exist. Aspirin users are therefore still at continuing risk of LGIB even years 
after aspirin therapy. 
History of GIB or peptic ulcer are generally considered to be a risk factor for GIB. In 
this study, risk factors analysis also showed that history of GIB or peptic ulcer is an 
important risk factor of GIB in patients who used aspirin after H. pylori eradication, 
irrespective of whether they are new or chronic aspirin users. There was a 2.8-fold 
increase in GIB risk among those with past history of peptic ulcer or GIB, which was 
consistent with previous studies.37, 38 Our study also found that, among patients without 
history of GIB or peptic ulcer, new aspirin users still have a higher risk of GIB than 
chronic users. According to current recommendations, long-term gastroprotective agent 
is recommended to high-risk patients including older age, previous GIB, peptic ulcer 
or ulcer complications, concomitant use of NSAIDs, anticoagulants, other antiplatelet 
drugs or other drugs increasing GIB risk.10, 39 Our subgroup analyses also confirmed 
that gastroprotective agents reduced the risk of aspirin related GIB among elderly ( 60 
years) and those with concurrent use of NSAIDs or other anti-platelet therapies. To our 
knowledge, there is no recommendation that specifically emphasized the higher risk of 
bleeding during the early course of aspirin treatment in patients after treatment for H. 
pylori. Hence, prophylactic gastroprotective agents are particularly warranted during 
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this initial period of aspirin treatment. As yet, gastroprotective agents could not reduce 
the risk of LGIB which may account for the non-declining risk of LGIB with time. 
The strengths of this study are the inclusion of a large cohort of H. pylori subjects who 
had received eradication therapy based on the comprehensive healthcare database in 
Hong Kong which captures all bleeding episodes, concurrent medical illnesses and 
medications usages. In addition to UGIB, we have also demonstrated the high 
incidences of LGIB in aspirin users who had received treatment for H. pylori. To adjust 
for potential differences in the baseline characteristics between new and chronic aspirin 
users in this study, we had used multiple models including PS matching and weighting 
(IPTW and MW) to adjust for various potential biases. Time-dependent Cox regression 
model were also used to evaluate the time-dependent effect of aspirin, and other 
covariates in multivariable model on GIB. 
Immortal time bias is an important methodological consideration which was common 
in observational studies.40, 41 However, when comparing new and chronic aspirin users, 
there should be minimal immortal time bias as both new and chronic users have same 
start point as the date of first aspirin prescription after H. pylori eradication. To further 
minimize immortal bias, we have also adopted time-dependent regression models in 
which all medications were treated as time-varying covariates.  
Our study has limitations. First, post-treatment H. pylori statuses were not available in 
the electronic database and the success of treatment was only inferred by the needs of 
retreatment. Some patients who failed H. pylori eradication might not receive further 
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therapy due to various reasons. Nonetheless, the overall retreatment rate of this study 
(11%) was comparable to the failure rate of clarithromycin-based triple therapy in a 
prospective study conducted in Hong Kong during the same period.42 To verify the 
success of H. pylori eradication, we had performed a validation study of 51 bleeding 
patients from our centre who had been retested for H. pylori. Second, this study did not 
evaluate the independent effect of H. pylori on the risk of GIB or the interaction 
between H. pylori and aspirin, as only H. pylori eradicated subjects were included. 
Ideally, this study should include a control group of H. pylori infected patients with no 
prior treatment, but this may pose ethical issues not to treat infected subjects, 
particularly before starting aspirin therapy. The lack of a group of patients without H. 
pylori infection is another limitation of this study. However, it has been shown that the 
recurrent bleeding risk among low-dose aspirin users after H. pylori eradication did not 
differ from average risk individuals.8 Third, the follow up duration of the three groups 
were different due to higher censoring rate from bleeding and shorter duration of aspirin 
usage in new users. As yet, the bleeding rate was the lowest among non-users with the 
longest follow up. Fourth, the electronic database could only determine the prescription 
and dispension but not the actual compliance to aspirin. Lastly, though various models 
were used to adjust for potential bias including competing risk analysis and time-
dependent regression, it is possible that some residual confounders may not be 
adequately adjusted. Despite these potential caveats, our findings support that H. pylori 
eradication is not risk proof in preventing subsequent GIB in aspirin users, particularly 
among new users and for the prevention of LGIB. 
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CONCLUSION 
In this study involving a large cohort of patients who had received H. pylori eradication 
therapy, we showed that both new and chronic aspirin users continued to have a 
significantly higher risk of hospitalizations for GIB than non-users. The risk of GIB, 
UGIB in particular, was significantly higher for new aspirin users when compared to 
chronic aspirin users during the initial 6-month of aspirin treatment. LGIB became 
more frequent than UGIB among aspirin users who had received H. pylori treatment. 
Although treatment with gastroprotective agents appeared to reduce the risk of GIB 
after H. pylori treatment, the risks of LGIB between new and chronic aspirin users 
continued and showed no trend of decline.  
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Figure Legends 
 
Figure 1 Incidence rates of hospitalization for all GIB, UGIB and LGIB during the 
follow-up period in new aspirin users, chronic users and non-users, and the 
corresponding relative risks between different groups. 
 
Figure 2 Kaplan-Meier curves for the proportion of patients who were free from GIB. 
A: GIB in all new aspirin users, chronic users and non-users; B: GIB in matched new 
aspirin users vs. chronic aspirin users. 
 
Figure 3 Kaplan-Meier curves of GIB (A) and UGIB (B) in the landmark analysis 
with the splitting time of 6-month (— chronic aspirin users; --- new aspirin users) 
 
Figure 4 Risk factors of hospitalization for GIB among aspirin users 
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Table 1 Baseline characteristics of new aspirin users, chronic aspirin users and non-
users 
Characteristics 
Non-users 
(n = 48,908) 
Before matching* After matching* 
New users 
(n = 6,985) 
Chronic users 
(n = 5,545) 
New users 
(n = 2,801) 
Chronic users 
(n = 2,801) 
Age at start point (year) † 
51.0 (43.0, 
60.0) 
67.0 (59.0-77.0) 68.0 (60.0-76.0) 
69.0 (59.0, 
78.0) 
68.0 (60.0, 
76.0) 
Gender (Male, %) 21,575 (44.1) 3,736 (53.5) 3,273 (59.0) 1,368 (48.8) 1,530 (54.6) 
Baseline conditions (%)      
GIB or ulcer history 7168 (14.7) 1,466 (21.0) 1,293 (23.3) 655 (23.4) 589 (21.0%) 
Ischemic heart disease 295 (0.6) 304 (4.4) 2,036 (36.7) 304 (10.9) 298 (10.6) 
Stroke 195 (0.4) 186 (2.7) 1,380 (24.9) 186 (6.6) 191 (6.8) 
Hypertension 1,985 (4.1) 1,562 (22.4) 2,060 (37.2) 818 (29.2) 749 (26.7) 
Diabetes 1488 (3.0) 973 (13.9) 1,313 (23.7) 526 (18.8) 506 (18.1) 
Renal disease 362 (0.7) 356 (5.1) 276 (5.0) 173 (6.2) 132 (4.7) 
Intracranial hemorrhage 156 (0.3) 87 (1.3) 64 (1.2) 30 (1.1) 32 (1.1) 
Cirrhosis 297 (0.6) 65 (0.9) 19 (0.3) 15 (0.5) 14 (0.5) 
Medications (%)      
Gastroprotective agents 36,208 (74.0) 6,285 (90.0) 5,173 (93.3) 2,585 (92.3) 2,579 (92.1) 
Other antiplatelet drugs 258 (0.5) 1,358 (19.4) 1,016 (18.3) 463 (16.5) 438 (15.6) 
NSAIDs 19,636 (40.1) 1,247 (17.9) 1,142 (20.6) 596 (21.3) 574 (20.5) 
Anticoagulants 405 (0.8) 301 (4.3) 270 (4.9) 136 (4.9) 146 (5.2) 
Corticosteroids 2,626 (5.4) 556 (8.0) 419 (7.6) 238 (8.5) 213 (7.6) 
SSRI 3,020 (6.2) 477 (6.8) 356 (0.6) 217 (7.7) 180 (6.4) 
Bisphosphonate 466 (1.0) 96 (1.3) 82 (1.5) 52 (1.9) 44 (1.6) 
† Variables expressed as median and interquartile range. * Absolute standardized differences 
between new and chronic users before or after matching (ASD) are showed in the Supplementary 
Figure 3. 
GIB, gastrointestinal bleeding; NSAIDs, nonsteroidal anti-inflammatory drugs; SSRI, selective 
serotonin reuptake inhibitors; Gastroprotective agents include proton pump inhibitors and 
histamine type-2 receptor antagonists. 
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Table 2 Results of time-dependent regression models comparing new with chronic 
aspirin users in patients after H. pylori eradication 
 
† Propensity scores or weights were calculated based on age, sex, baseline conditions and 
concomitant medications; ‡ Adjusted for age, sex, baseline conditions and concomitant medications 
which were included as time-varying covariates; § Time-by-covariate interactions in regression 
model, in which time indicates start points of each 3-month interval of the follow-up period, in terms 
of 0, 0.25, 0.5, 0.75 year, and so forth. 
PSM, propensity score matching; PSMW, propensity score matching weighting; IPTW, inverse 
probability of treatment weighting; GIB, gastrointestinal bleeding; UGIB, upper gastrointestinal 
bleeding; LGIB, lower gastrointestinal bleeding; HR, hazard ratio; CI, confidence interval. 
 
Models Variables 
GIB UGIB LGIB 
HR (95% CI) P HR (95% CI) P HR (95% CI) P 
Univariate Cox 
regression model with 
original samples 
New users 1.16 (0.98-1.38) 0.080 1.12 (0.86-1.47) 0.396 1.19 (0.92-1.55) 0.187 
Including a time-by-
covariate interaction 
New users 1.41 (1.10-1.80) 0.007 - - - - 
New users*time§ 0.92 (0.85-0.998) 0.04 - - - - 
PSM† 
New users 1.89 (1.29-2.70) <0.001 1.30 (0.85-1.99) 0.234 1.94 (1.29-2.91) 0.001 
New users*time 0.89 (0.80-1.01) 0.063 - - - - 
MW† 
New users 1.80 (1.32-2.46) <0.001 2.00 (1.21-3.20) 0.007 1.49 (1.07-2.07) 0.018 
New users*time 0.87 (0.80-0.95) 0.002 0.82 (0.70-0.96) 0.015 - - 
IPTW† 
New users 1.81 (1.34-2.44) <0.001 1.73 (1.09-2.73) 0.019 1.61 (1.15-2.25) 0.006 
New users*time 0.87 (0.80-0.95) 0.003 0.84 (0.72-0.97) 0.018 - - 
Multivariable Cox 
regression model‡ 
New users 1.74 (1.32-2.29) <0.001 1.63 (1.08-2.46) 0.020 1.53 (1.11-2.10) 0.009 
New users*time 0.91 (0.84-0.99) 0.025 0.91 (0.79-1.04) 0.154 - - 
